Liquid biopsy for detecting and characterizing cell-free circulating tumor nucleic acid or circulating tumor cells is increasingly used in cancer testing.
For most applications, liquid biopsy (LBx) only requires a simple blood draw, offers simpler sample collection logistics and faster overall time to results. It provides a very attractive option especially when tissue samples may be challenging or impractical to obtain. Liquid biopsy can be used to non-invasively characterize primary tumors and metastases for diagnosis, real-time monitoring of tumor evolution, and treatment response. Liquid biopsy is now commonly used to aid data collection for prospective clinical trials.
Key Highlights:
- NeoGenomics offers a family of liquid biopsy test methods, covering a broad range of important cancer biomarkers such as hotspot genes, tumor suppressor genes, copy number variation (CNV), gene fusions, single nucleotide variants (SNVs), and insertions and deletions (Indels)
- NeoGenomics’ LBx tests non-invasively characterize primary tumor drivers, resistance mutations, and hotspots for real-time and serial monitoring of tumor evolution and treatment response
- NeoGenomics’ LBx offerings cover actionable markers of all solid tumor indications supported by FDA/EMA labels, NCCN and ESMO guidelines, and clinical trials
- Sample types include whole blood, plasma, and cfDNA/RNA extracted from plasma
- Our RareCyte® liquid biopsy service provides an unbiased workflow for circulating tumor cell (CTC) capture, enumeration, and single-cell isolation
| Liquid Biopsy Tools | Description |
|---|---|
| NEO | PanTracer™ LBx | NEO | PanTracer LBx is a comprehensive liquid biopsy panel with over 500 genes for genomic profiling for solid tumor patients from cfDNA. The panel detects all major variant classes (SNVs, InDels, Fusions, CNVs) as well as genomic signatures including MSI and bTMB scores for cancer research and discovery application. PanTracer LBx enables detection of variants down to 0.2% VAF with a >99.9% specificity. |
| RareCyte CTC | CTCs are implicated in the origin of cancer metastasis. Studies have shown there is an association between the number of CTCs and the prognosis and response to therapy. NeoGenomics’ RareCyte service offers practical deployment of CTC-based liquid biopsy with a highly sensitive, accurate, unbiased, and reproducible workflow. In addition, the ability of single-cell isolation will also allow for downstream investigation of cancer cell biomarker expression and mutational status. |
Contact Us To Get Started!
Work with us – your premier oncology partner – to optimize cancer care for patients